K Cosansu1, C M Ureyen2, S Yılmaz3. 1. Education and Research Hospital, Department of Cardiology, Sakarya University, 54100, Sakarya, Turkey. kahraman141@gmail.com. 2. Department of Cardiology, Antalya Education and Research Hospital, Antalya, Turkey. 3. Education and Research Hospital, Department of Cardiology, Sakarya University, 54100, Sakarya, Turkey.
Abstract
BACKGROUND: The negative impact of atrial fibrillation (AF) on health-related quality of life has been extensively documented. The aim of this study was to compare the Hospital Anxiety and Depression Scale (HADS) scores of patients with non-valvular AF during warfarin administration and after switching to novel oral anticoagulants (NOACs). METHODS: The study comprised 100 consecutive patients on warfarin treatment between July 2018 and January 2019 for whom a transition to NOACs was planned. All patients completed the HADS at the start of the study and at least 3 months after that date. RESULTS: The mean value of HADS-A (5.9 ± 2.1 vs. 4.4 ± 1.6, p < 0.001) and HADS-D (4.4 ± 1.7 vs. 3.7 ± 1.4, p < 0.001) scores was significantly higher in patients when they used warfarin than when they switched to NOACs. Analysis revealed that there was a significant correlation between HADS-A and HADS-D scores with age and history of bleeding (p < 0.001). The highest scores were found for patients with a history of bleeding and age ≥75 years (p < 0.001). CONCLUSION: Our study demonstrates that patients with nonvalvular AF under treatment with NOACs had lower HADS-A and HADS-D scores compared with patients on warfarin treatment. These findings suggest that NOACs may increase the quality of life and decrease morbidity and mortality by reducing anxiety and depression.
BACKGROUND: The negative impact of atrial fibrillation (AF) on health-related quality of life has been extensively documented. The aim of this study was to compare the Hospital Anxiety and Depression Scale (HADS) scores of patients with non-valvular AF during warfarin administration and after switching to novel oral anticoagulants (NOACs). METHODS: The study comprised 100 consecutive patients on warfarin treatment between July 2018 and January 2019 for whom a transition to NOACs was planned. All patients completed the HADS at the start of the study and at least 3 months after that date. RESULTS: The mean value of HADS-A (5.9 ± 2.1 vs. 4.4 ± 1.6, p < 0.001) and HADS-D (4.4 ± 1.7 vs. 3.7 ± 1.4, p < 0.001) scores was significantly higher in patients when they used warfarin than when they switched to NOACs. Analysis revealed that there was a significant correlation between HADS-A and HADS-D scores with age and history of bleeding (p < 0.001). The highest scores were found for patients with a history of bleeding and age ≥75 years (p < 0.001). CONCLUSION: Our study demonstrates that patients with nonvalvular AF under treatment with NOACs had lower HADS-A and HADS-D scores compared with patients on warfarin treatment. These findings suggest that NOACs may increase the quality of life and decrease morbidity and mortality by reducing anxiety and depression.
Entities:
Keywords:
Atrial fibrillation; Hemorrhage; Non-vitamin K novel oral anticoagulant; Quality of life; Warfarin
Authors: Helen T Paradise; Dan R Berlowitz; Al Ozonoff; Donald R Miller; Elaine M Hylek; Arlene S Ash; Guneet K Jasuja; Shibei Zhao; Joel I Reisman; Adam J Rose Journal: J Gen Intern Med Date: 2014-02-19 Impact factor: 5.128
Authors: M P van den Berg; R J Hassink; A E Tuinenburg; E F van Sonderen; J D Lefrandt; P J de Kam; I C van Gelder; A J Smit; R Sanderman; H J Crijns Journal: Eur Heart J Date: 2001-02 Impact factor: 29.983